A: H. Lee Moffitt Cancer Center (“Moffitt”) is collaborating with Deerfield Management Company, an investment firm dedicated to advancing healthcare, to accelerate the translation of research emerging from Moffitt. Bayfield Therapeutics, LLC, is a private company wholly owned by affiliates of Deerfield Management formed to facilitate this collaboration. Its objective is to fund projects aimed at discovering novel therapeutics that have the potential to cure life altering diseases. This collaboration will rely on the novel insights Moffitt researchers and clinicians have and will leverage Deerfield's expertise in accelerating state-of-the-art drug development. Deerfield has committed up to $130 million and may provide additional scientific and operational support.

A: Principal Investigators whose principal employer is Moffitt or who have a faculty appointment at Moffitt and are therefore subject to Moffitt’s institutional policies are eligible to apply.

A: Interested faculty should reach out to innovation@moffitt.org for more information on proposal submission.